Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

SystImmune

Private
#Oncology#Antibodies#ADC

Clinical-stage biotechnology company in Redmond, Washington, developing bispecific and multi-specific antibodies and antibody-drug conjugates for solid tumor and hematologic cancers; its September 2026 FDA IND clearance for SI-B037 was the company's first IND built on New Approach Methodologies.

Company Info

Sector:Biotechnology
Headquarters:Redmond, Washington, USA
Founded:2014
Website:systimmune.com/

Upcoming Milestones & Key Dates

2027
Clinical

First-in-human study start for SI-B037

Clinical Development Pipeline

SI-B037

Target: Bispecific antibody
Solid tumors
Preclinical
Phase 1
Phase 2
Phase 3
Approved

BL-B01D1

Target: EGFR x HER3 bispecific antibody-drug conjugate
EGFR-mutant and HER3-expressing solid tumors
Preclinical
Phase 1
Phase 2
Phase 3
Approved

SI-B001

Target: EGFR x HER3 bispecific antibody
Solid tumors
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Jie D'Elia, PhD

Chief Executive Officer

Jonathan Cheng, MD

Chief Medical Officer

Careers & Job Openings

See all open roles

All departments
Multiple locations
Apply Now →